These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Criteria toward the definition of nonmetastatic gestational trophoblastic disease after hydatidiform mole.
    Author: Kohorn EI.
    Journal: Am J Obstet Gynecol; 1982 Feb 15; 142(4):416-9. PubMed ID: 6277194.
    Abstract:
    The administration of chemotherapy to a patient with persistently elevated titers of hCG without metastases after hydatidiform mole implies a diagnosis of nonmetastatic gestational trophoblastic neoplasia (NMGTN). At present, a diagnosis of NMGTN following evacuation of hydatidiform mole is usually made after a plateau of three values of hCG over 2 weeks (days x, x + 7, x + 14), and patients are given chemotherapy on the basis of such a plateau. The frequency of the diagnosis of NMGTN from four United States Centers is presently 26% and this compares with a frequency of choriocarcinoma of 16% in the prechemotherapy era. Data are presented to demonstrate that a plateau of 3 or 4 weeks may be justified before a diagnosis of NMGTN is made and chemotherapy is given in patients who may be followed up closely.
    [Abstract] [Full Text] [Related] [New Search]